Breakthrough Antibody Research Published
Dixon, Calif., July 25, 2001 -- Lexrite Labs last month announced the publication of breakthrough medical research in the July 17, 2001 issue of the Proceedings of the National Academy of Sciences validating the Company's innovative infinite-affinity antibody platform technology to permanently bind antibodies and radioactive carriers to potentially deliver effective treatment for a variety of cancers. The new binding technique, developed by the company's founders, creates antibody-ligand pairs that exhibit an essentially infinite level of affinity because the antibody and ligand become covalently bound to each other. In essence, the antibody recognizes and permanently binds to a radioactive carrier or other therapeutically active molecule and forms a permanent chemical bond, which can thereby deliver the maximum amount of therapy directly to a tumor cell while sparing healthy tissues.
As highlighted in the July 23, 2001 issue of Chemical & Engineering News, potential applications of this important new platform technology include not only targeted delivery of radiation therapy but also biosensing, bioanalytical detection and improved targeting of effector molecules to specific cells of interest for imaging or therapy.
During the last several years, Claude F. Meares, Ph.D., chemistry professor at the University of California, Davis, and coworkers have worked to develop an antibody engineered to recognize and "stick" to a radioactive carrier, resulting in the significant enhancement of the binding affinity of the antibodies of interest. Encouraged by the success of their work, and the recently published research on the effectiveness and potential of this proprietary infinite-affinity antibody technology, Dr. Meares and colleagues have founded Lexrite Labs, in Dixon, California, to commercialize the discovery.
Dr. Meares, Chief Scientific Advisor of Lexrite Labs, commented, "The achievement of infinite affinity is a major conceptual breakthrough in antibody engineering which could lead to significant advances in cancer therapy and medical imaging. The potentially new class of anti-cancer drugs resulting from this discovery should make it easier to detect and kill cancer cells with fewer side effects, such as nausea and hair loss, commonly associated with chemotherapy. This revolutionary therapeutic platform may lead to new and more effective treatments for a wide variety of cancers including non-Hodgkin's lymphoma, colorectal, breast and ovarian malignancies."
Lexrite Labs, located in Dixon, California, is focused on the development of new targeting molecules with infinite affinity. Lexrite intends to pursue collaborative relationships and alliances with a broad spectrum of biotechnology and pharmaceutical companies to incorporate Lexrite's proprietary technology into a new generation of cancer treatments.
Rebecca Robinson, Chief Operating Officer, Lexrite Labs, 707-678-8444, [email protected]
Coastal Post Home Page